Clinical Blogs

mikehighressquare-4

Our Commitment During COVID-19

A Message from myMatrixx President, Mike Cirillo. myMatrixx works hard, every day, to be your trusted partner for better workers’ compensation PBM support. That means bringing innovative solutions to your problems, identifying opportunities to improve the health and well-being of your injured...
Learn more

Making Sense of Workers’ Comp Pharmaceuticals During COVID-19

When the COVID-19 pandemic became a serious concern all the way back in March, businesses had to find a way to adapt. Since it is abundantly clear that this is in no way a short-term problem, it is all the more critical to start to look back and analyze some of the data from the earlier months. ...
Learn more
Phil Walls_website_800x800

The Future of Pharmacy

When I graduated from pharmacy school over forty years ago I had a vision for a future of pharmacy where pharmacists were recognized and compensated for their knowledge of medication as opposed to the dispensing of medication, and I am very proud of the fact that today, at myMatrixx, I have dozens...
Learn more
Brian Williams

Pfizer’s Opioid Embeda to Be Discontinued

The long and winding road for the drug Embeda® (morphine sulfate and naltrexone hydrochloride) appears to be nearing its end. The manufacturer, Pfizer, has not yet released any public information, but the Food and Drug Administration (FDA) has posted on its website the date of November 15, 2019,...
Learn more
UPDATED-Michael-Nguyen-Headshot-800x800

New Federal Guideline Aims to Clarify Safe Opioid Weaning Practices

The Centers for Disease Control and Prevention (CDC) was the first to sound the alarm on the U.S. opioid epidemic. For years, the CDC tracked the epidemic and shared the alarming statistics with the medical community in hopes that it would make an impact, yet opioid overdose deaths continued to rise....
Learn more
Brian Williams cropped

The Financial Impact of Generic Lyrica is a Big Deal

Lyrica was initially approved by the FDA in 2004. Following approval for further indications in 2007 and again in 2012, Lyrica’s patent was finally set to expire at the end of 2018. Since Lyrica is routinely seen as one of the higher spend medications in Workers’...
Learn more
FDA logo

First Generic for the Opioid Antagonist Narcan Approved by the FDA

On April 19, the Food and Drug Administration (FDA) granted final approval of the first generic for naloxone nasal spray, more commonly known as Narcan. Naloxone is an opioid antagonist and this life-saving medication can stop or reverse the effects of an opioid overdose.“In the wake of the opioid...
Learn more
UPDATED-Michael-Nguyen-Headshot-800x800

The FDA Tackles the Approval of New Opioid Medication

The U.S Food and Drug Administration (FDA) recently reviewed two new opioid medications for approval – Dsuvia® and Olinvo®. The crisis of opioid addiction is a great concern in our country. The FDA is taking steps to actively confront this crisis, while also keeping the needs of the patients and...
Learn more
Brian Williams cropped

Study Shows Compounded Creams No Better Than Placebo Creams

On February 5, the Annals of Internal Medicine published results from a study that aimed to determine the efficacy of compounded creams utilized for chronic pain. Researchers from Walter Reed National Military Medical Center separated 399 patients into groups of those experiencing neuropathic pain,...
Learn more